Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | ACACB | O00763 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21150125 | 1.00 | SMN1; SMN2 (0.35) | SMN1; SMN2GAACA12CA1CA2 | |
| SCHEMBL21150126 | 0.81 | HTT (0.39) | SMN1; SMN2GAA | |
| SCHEMBL20908169 | 0.81 | HTT (0.39) | SMN1; SMN2GAA | |
| SCHEMBL23637708 | 0.79 | — | — | |
| SCHEMBL8141423 | 0.79 | SMN1; SMN2 (0.39) | SMN1; SMN2GAACA12CA1CA2 | |
| SCHEMBL8755734 | 0.79 | SMN1; SMN2 (0.39) | SMN1; SMN2GAACA12CA1CA2 | |
| SCHEMBL10125333 | 0.79 | SMN1; SMN2 (0.39) | SMN1; SMN2GAACA12CA1CA2 | |
| SCHEMBL25118258 | 0.77 | SMN1; SMN2 (0.33) | SMN1; SMN2CA12CA1CA2MMP1 | |
| SCHEMBL12075678 | 0.75 | SMN1; SMN2 (0.32) | SMN1; SMN2CA12CA1CA2MMP1 | |
| SCHEMBL14864784 | 0.75 | SMN1; SMN2 (0.32) | SMN1; SMN2CA12CA1CA2MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10774053-B2 | HIV protease inhibitors | GILEAD SCIENCES, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190210978-A1 | HIV PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774053-B2 | HIV protease inhibitors | PRSS1, SERPINB1, FURIN | SMN1; SMN2 2891/4885GAA 80/4885CA12 2993/4885 |
| US-20190210978-A1 | HIV PROTEASE INHIBITORS | PRSS1, SERPINB1, HPN | SMN1; SMN2 3372/4885GAA 130/4885CA12 2689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.